Solid Biosciences Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Solid Biosciences Inc. (SLDB) reported Net Income (Loss) Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2020-03-12
- Solid Biosciences Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-12-31 was $0.00.
- Solid Biosciences Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-09-30 was $0.00.
- Solid Biosciences Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-06-30 was $0.00.
- Solid Biosciences Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-03-31 was -$1.06M.
- Solid Biosciences Inc. net income (loss) attributable to noncontrolling interest for fiscal 2018 was $0.00.
- Solid Biosciences Inc. net income (loss) attributable to noncontrolling interest for fiscal 2017 was -$1.06M.
- Solid Biosciences Inc. net income (loss) attributable to noncontrolling interest for fiscal 2016 was -$2.23M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2020-03-12 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | -$1.06M 10-K · filed 2020-03-12 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $0.00 derived: sum of 2 quarters · filed 2018-11-13 | -$1.06M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | -$1.06M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$1.06M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$2.23M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |